. Author manuscript; available in PMC: 2019 Feb 1.

Published in final edited form as: Mov Disord. 2017 Dec 4;33(2):243–247. doi: 10.1002/mds.27247

Table 1.

Potential study population estimates

Populations	USA	Europe	Total

Manifest HD
(High estimate: prevalence 12:100,000)^*	38,280	89,160	127,440
(Low estimate: prevalence 7:100,000)^*	22,330	52,010	74,340

Estimates of premanifest HDGEC
(High estimate: prevalence 12:100,000^**)	114,840	267,480	383,320
(Low estimate: prevalence 7:100,000^**)	66,990	156,030	223,020

Current uptake of predictive genetic testing of 5%
(High-Low prevalence estimates)	5,742-3,350

Current uptake of predictive genetic testing of 17.4%^***		46,542–27,149
(High-Low prevalence estimates)		46,542–27,149

Current uptake of predictive genetic testing
(High-Low prevalence estimates)			52,284 – 30,499

Prevalence estimates (low and high) derived from Rawlins et al. (2016).¹⁹

^**

Premanifest HD is estimated to have 3× the prevalence of Manifest HD. HDGEC: Huntington’s disease gene expansion carriers

^***

Predictive testing in Europe taken from Baig et al (2016).⁵